Tonix Pharm Holdings (TNXP) |
|
0.2452 0.011 (4.83%)
|
01-26 00:51 |
|
Open: |
0.2351 |
Pre. Close: |
0.2339 |
|
High:
|
0.25 |
Low:
|
0.2322 |
|
Volume:
|
15,271,871 |
Market Cap:
|
122M |
|
|
|
|
Tonix Pharmaceuticals Holding Corp. discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 for the prevention of COVID-19. The company's lead CNS candidate is TNX-102 SL, a sublingual tablet formulation of cyclobenzaprine for fibromyalgia, and for the treatment of agitation in Alzheimer's disease, posttraumatic stress disorder (PTSD), and alcohol use disorder. Its products include TNX-1300 for the treatment of cocaine intoxication; TNX-601 CR for depression disorder, PTSD, and neurocognitive dysfunction from corticosteroids; and TNX-1900 for migraine and craniofacial pain treatment. Its preclinical pipeline includes TNX-1600 for PTSD, depression, and attention deficit hyperactivity disorder; TNX-1700 for gastric and pancreatic cancers; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500, a monoclonal antibody anti-CD40-L for organ transplant rejection autoimmunity; and TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome. It also develops TNX-2100, a COVID-19 skin test. It has collaboration agreements with Southern Research Institute, Columbia University, the University of Alberta, and Massachusetts General Hospital. The company was incorporated in 2007 and is headquartered in Chatham, New Jersey. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.25 - 0.252 |
0.252 - 0.253 |
|
Low:
|
0.227 - 0.229 |
0.229 - 0.23 |
|
Close:
|
0.248 - 0.25 |
0.25 - 0.252 |
|
Technical analysis |
as of: 2022-01-25 4:27:38 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 0.40  One year: 0.50 |
| Support: |
Support1: 0.20 Support2: 0.17 |
| Resistance: |
Resistance1: 0.34 Resistance2: 0.43 |
| Pivot: |
0.30 |
| Moving Average: |
MA(5): 0.25 MA(20): 0.32
MA(100): 0.49 MA(250): 0.86 |
| MACD: |
MACD(12,26): -0.05 Signal(9): -0.04 |
| Stochastic oscillator: |
%K(14,3): 11.37 %D(3): 6.06 |
| RSI: |
RSI(14): 27.75 |
| 52-week: |
High: 2.12 Low: 0.20 Change(%): -75.0 |
| Average Vol(K): |
3-Month: 17351 10-Days: 14875 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.TNXP has closed above bottom band by 20.3%. Bollinger Bands are 54.8% wider than normal. The large width of the bands suggest high volatility as compared to Tonix Pharm Holdings's normal range. The bands have been in this wide range for 3 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Fri, 21 Jan 2022
Why is Tonix Pharmaceuticals Holding Corp. (TNXP) stock gloomy today? - Stocks Telegraph
Tue, 18 Jan 2022
Why AMC and GameStop Are Tumbling Today - Motley Fool
Tue, 04 Jan 2022
Tonix Pharmaceuticals Announces Exclusive Option and Research Collaboration with Kansas State University to Develop LNP-Free mRNA Vaccines - Yahoo Finance
Mon, 03 Jan 2022
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
Wed, 15 Dec 2021
Tonix Pharmaceuticals Added to the Nasdaq Biotechnology Index - Yahoo Finance
Thu, 21 Oct 2021
Tonix Pharmaceuticals to Participate in BIO-Europe Digital 2021 - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
496 |
| Shares Float (M) |
439 |
|
% Held by Insiders
|
0.06 |
|
% Held by Institutions
|
17.96 |
|
Shares Short (K)
|
10,010 |
|
Shares Short P. Month (K)
|
8,650 |
Stock Financials |
|
EPS
|
-0.277 |
|
EPS Est This Year
|
-3.020 |
|
EPS Est Next Year
|
-2.470 |
|
Book Value (p.s.)
|
0.500 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-35.3 |
|
Return on Equity (ttm)
|
-60.2 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-0.161 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-67 |
|
Levered Free Cash Flow (M)
|
-56 |
Stock Valuations |
|
PE Ratio
|
-0.89 |
|
PEG Ratio
|
|
|
Price to Book value
|
0.49 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
2019-10-31 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
